Form SC 13G/A BIOCRYST PHARMACEUTICALS Filed by: VANGUARD GROUP INC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
BioCryst Pharma (BCRX) PT Raised to $21 at Piper Sandler, 'we continue to recommend shares'
November 4, 2024 2:20 PM ESTPiper Sandler analyst Tyler Van Buren raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $21.00 (from $20.00) while maintaining a Overweight rating.
The analyst comments "Remain OW rated on BCRX shares after this mornings Q324 Orladeyo beat and narrowed FY24 Orladeyo revenue... More
BofA Securities on BioCryst Pharma (BCRX) 'Stock’s weakness offers particularly attractive entry point'
November 4, 2024 2:06 PM EST(Updated - November 4, 2024 2:16 PM EST)
BofA Securities analyst Tazeem Ahmad reiterated a Buy rating and $11.00 price target on BioCryst Pharma (NASDAQ: BCRX)
The analyst comments "BCRX reported $116.3mn in 3Q Orladeyo sales, slightly ahead of our $113.7mn and consensus $112.6mn. Mgmt highlights strong patient demand, noting US start forms were up 14.2% over the past 12 months and the paid drug rate improved to 74.8% (2Q: 74.4%). Additionally, 67 new US prescribers were added in 3Q, which is the highest add in the past eight quarters. The company narrowed FY24 Orladeyo sales guidance to... More
